MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that the U.S. Food and Drug Administration has granted premarket approval for the NeuroPace® RNS® System, a treatment for adults with partial onset seizures that...
Nov. 14, 2013 – This month, the Epilepsy Foundation and Lundbeck joined together in a nationwide effort to bring information about managing seizures to people living with epilepsy and their families. At the center of the initiative is a new...
Trokendi XR Helps Partial Onset and Seizures Associated with Lennox-Gastaut Syndrome The Food & Drug Administration has issued final approval for Trokendi XR, an extended-release oral formulation of topiramate for treatment of epilepsy...
DEA Delays Threaten to Hurt People Living with Seizures The Epilepsy Foundation calls on the Drug Enforcement Administration (DEA) to revise its process for reviewing new treatments. The current method dampens innovation and lacks transparency...
A newly-released report from Pharmaceutical Research and Manufacturers of America (PhRMA) has revealed that nearly 450 new medicines are in development to treat neurological disorders, including 28 for epilepsy and seizures. "The Epilepsy...

Pages